Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

The Journal of clinical investigation - 1 Aug 2003

Huang Yufeng, Haraguchi Masashi, Lawrence Daniel A, Border Wayne A, Yu Ling, Noble Nancy A

Abstract excerpt

In fibrotic renal disease, elevated TGF-beta and angiotensin II lead to increased plasminogen activator inhibitor type 1 (PAI-1). PAI-1 appears to reduce glomerular mesangial matrix turnover by inhibiting plasminogen activators, thereby decreasing plasmin generation and plasmin-mediated matrix de...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding, Competitive
Share to Extracellular Matrix
Share to Fibronectins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glomerulonephritis

Share to Isoantibodies

Share to Plasminogen Activator Inhibitor 1

Share to Transforming Growth Factor beta1

Share to Vitronectin

Source

Open in PubMed Open full text

Identifiers

PMID: 12897205
DOI: 10.1172/JCI18038
PMCID: PMC166295

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12897205-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.PMID 12897205Read ↗

Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.Semantic proximity Read ↗

Renal fibrosis: not just PAI-1 in the sky.Semantic proximity Read ↗

Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.Semantic proximity Read ↗

Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.Semantic proximity Read ↗

A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes.Semantic proximity Read ↗

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation.Semantic proximity Read ↗

Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.Semantic proximity Read ↗

Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.Semantic proximity Read ↗

Endogenous urokinase lacks antifibrotic activity during progressive renal injury.Semantic proximity Read ↗

Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor-1 produces elevated collagen accumulation in normal and keloid fibroblasts.Semantic proximity Read ↗

Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a).Semantic proximity Read ↗

Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.